Is MGNX or MLTX more undervalued in 2026?

CirclFi compares MacroGenics, Inc. (MGNX) and MoonLake Immunotherapeutics (MLTX) using 13 institutional-grade valuation models. MGNX has a Quality of Company score of 6.2/10 while MLTX scores 4.0/10.

Which is a better buy — MGNX or MLTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MGNX and MLTX valuations compare?

MGNX at $4.16 and MLTX at $19.18 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MGNX vs MLTX Valuation Comparison 2026 — Intrinsic Value Analysis

MGNX

Pharmaceutical Preparations

MacroGenics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$4.16

Last close

Models

12/13

Active

MLTX

Pharmaceutical Preparations

MoonLake Immunotherapeutics

Quality

4.0

out of 10

Value Trap

LOW

Price

$19.18

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	MGNX Fair Value	MGNX Upside	MLTX Fair Value	MLTX Upside
Bayesian DCF	Intrinsic	$1.13	-72.9%	$6.26	-67.4%
Earnings Power Value	Intrinsic	$9.04	+188.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.82	-80.2%	$0.45	-97.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MGNX vs MLTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MGNX vs MLTX — Which Stock Is More Undervalued?

MGNX scores higher with a 6.2/10 quality rating vs MLTX's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MacroGenics, Inc. (MGNX) and MoonLake Immunotherapeutics (MLTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MGNX currently trades at $4.16 with a QOC of 6.2/10, while MLTX trades at $19.18 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).